Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5617698 | 0.81 | MAPK9 (0.36) | MITFLMNATP53ALOX12HTT | |
| SCHEMBL5617593 | 0.79 | MITF (0.33) | MITFLMNATP53ALOX12HTT | |
| SCHEMBL5617600 | 0.79 | PIN1 (0.32) | — | |
| SCHEMBL5618412 | 0.77 | MITF (0.33) | MITFLMNATP53ALOX12HTT | |
| SCHEMBL5617979 | 0.73 | MAPK9 (0.35) | — | |
| SCHEMBL14439691 | 0.62 | ALDH1A1 (0.31) | MAPK1ALDH1A1MAPT | |
| SCHEMBL25121378 | 0.62 | LMNA (0.45) | MITFLMNATP53ALOX12HTT | |
| SCHEMBL14566671 | 0.62 | LMNA (0.45) | MITFLMNATP53ALOX12HTT | |
| SCHEMBL5617893 | 0.61 | LMNA (0.40) | MITFLMNATP53ALOX12HTT | |
| SCHEMBL14439694 | 0.59 | MAPT (0.34) | TP53MAPK1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203134-A1 | Benzimidazole Acetonitriles | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-30 | — | — | US | disclosed |
| EP-1667995-A1 | BENZIMIDAZOLE ACETONITRILES | Applied Research Systems ARS Holding N.V. (AN) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005026155-A1 | BENZIMIDAZOLE ACETONITRILES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203134-A1 | Benzimidazole Acetonitriles | PKD1, GPR119, CCNI | MITF 3064/4885LMNA 1032/4885TP53 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.